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Alpha-synuclein (αSyn) is encoded by the ﬁrst causal gene identiﬁed in Parkinson's disease (PD) and is themain
component of Lewy bodies, a pathological hallmark of PD. aSyn-based animalmodels have contributed to our un-
derstanding of PD pathophysiology and to the development of therapeutics. Overexpression of human wildtype
αSyn by viral vectors in rodents recapitulates the loss of dopaminergic neurons from the substantia nigra, anoth-
er deﬁning pathological feature of the disease. The development of a rat model exhibiting bimolecular ﬂuores-
cence complementation (BiFC) of αSyn by recombinant adeno-associated virus facilitates detection of the toxic
αSyn oligomers species. We report here neurochemical, neuropathological and behavioral characterization of
BiFC of αSyn in mice. Overexpression and oligomerization of αSyn through BiFC is detected by conjugated ﬂuo-
rescence. Reduced striatal dopamine and loss of nigral dopaminergic neurons are accompanied neuroinﬂamma-
tion and abnormalmotor activities. Ourmousemodelmay provide a valuable tool to study the role ofαSyn in PD
and to explore therapeutic approaches.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Parkinson's disease (PD) is the secondmost commonneurodegener-
ative disorder manifested by slowness in movement, muscular rigidity,
rest tremor, postural and gait impairment, and non-motor features.
Available dopaminergic treatments offer symptomatic relief. However,
there is currently no therapy to slow, halt, or reverse its progressive
course. Pathologically, loss of dopaminergic neurons in the substantia
nigra (SN) and presence of Lewy bodies and Lewy neurites in the resid-
ual neurons are hallmarks of PD (Braak and Del Tredici, 2009). Themain
component of Lewy bodies is insoluble aggregates of alpha-synuclein
(αSyn), a ubiquitously expressed neuronal protein. While native state
and functions of αSyn are not completely understood, increasing evi-
dence suggests that soluble oligomeric αSyn is the most toxic species
(Dehay et al., 2015; Kingwell, 2017). Although the etiology of PD is un-
clear, neuroinﬂammation appears to be an important contributor to its
pathogenesis (Hirsch et al., 2005; Hirsch and Hunot, 2009; Hirsch and
Vyas, 2012).
αSyn is encoded by SNCA, the ﬁrst gene identiﬁed to cause PD
(Spillantini et al., 1997). Multiple copies and point mutations of SNCA
lead to the early onset of familial PD, and αSyn also contributes the
basis of genetic risk of developing sporadic PD (Kalinderi et al., 2016).
Given the central role of αSyn in PD genetics and pathogenesis, various
animalmodels overexpressing eitherwildtype (WT) ormutant forms of
αSyn have been developed to model the disease and to develop thera-
pies. Among these models, viral vector-mediated overexpression of
αSyn offers several advantages in recapitulating dopaminergic patholo-
gy of PD (Koprich et al., 2017). Using targeted overexpression of human
WT αSyn in the SN by recombinant adeno-associated virus (AAV), we
and others demonstrated loss of nigral dopaminergic neurons and
neuroinﬂammatory responses in both rats and mice (Harms et al.,
2013; McFarland et al., 2009; Theodore et al., 2008). The development
of a bimolecular ﬂuorescence complementation (BiFC) assay in rats fa-
cilitates direct detection of overexpression of αSyn fused to the N- and
C- terminus half of venusYFP and formation of αSyn oligomers. The
ratmodel shows striatal gliosis, neuritic dystrophy and loss of nigral do-
paminergic neurons (Dimant et al., 2013).
Here we report systematical characterization of this BiFC system in
mice including neuropathological, neurochemical, synucleinopathic,
neuroinﬂammatory and behavioral changes. Time courses and dose re-
sponses were explored, with comparison to the original non-BiFC sys-
tem. Since mice are the most commonly used animal species in PD
research and most genetic probes are readily available in mice, our
mouse model may provide a valuable tool to explore new therapeutic
approaches for PD.
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2. Materials and Methods
2.1. Mice
Adult C57BL/6J mice (4–5 months old, male and female, weighing
25–30 g) from the Jackson laboratorywere used for all experiments. An-
imals were randomly assigned to different groups. Animals were main-
tained in home cages at constant temperature with a 12-h light/dark
cycle and free access to food and water. All experiments were per-
formed in accordance with a protocol approved by the Massachusetts
General Hospital Animal Care and Use Committee and in compliance
with the National Institute of Health guidelines for the use of experi-
mental animals.
2.2. Viral Vectors
BiFC vectors: (1) pAAV-CBA-Venus1-human αSyn -WPRE (V1S) by
inserting the human WT SNCA fused with N-terminus half of venusYFP
into the EcoRV and NheI sites of pAAV-CBA-WPRE vector; (2) pAAV-
CBA- human αSyn -venus2-WPRE (SV2) by inserting the human WT
SNCA fused with C-terminus half of venusYFP into the EcoRV and NheI
sites of pAAV-CBA-WPRE vector; (3) pAAV-CBA-venusYFP-WPRE
(venus) by inserting the venusYFP into the XhoI and NheI sites of
pAAV-CBA-WPRE vector (Dimant et al., 2013).
Non-BiFC vectors: (1) pAAV-CBA- human αSyn -WPRE (αSyn) by
inserting the human WT SNCA into the XhoI and NheI sites of pAAV-
CBA-WPRE vector (St Martin et al., 2007; Theodore et al., 2008);
(2) pAAV-CBA-WPRE empty vector (vector).
All vectors were packaged and puriﬁed in AAV serotype 8 by the
Mayo Clinic Viral Vector laboratory.
2.3. Stereotaxic Virus Injections
Mice were anesthetized by intraperitoneal injection of Avertin and
were placed in a stereotaxic frame. A total volume of 2 μl of viruswas in-
fused unilaterally at a rate of 0.1 ul/min into the left SN at coordinates at
AP 0.09, ML 0.12, and DV -0.43 cmwith lambda as a point of reference.
At the end of the injection, theneedle remained in place for 5min before
gradual removal.
The ﬁnal injection titers (genome copies (gc)/ml) were: 5.1 × 1012
for V1SSV2 (mixing V1S at 4.7 × 1012 and SV2 at 5.4 × 1012 with equal
volumes); 0.6 × 1012 and 4.4 × 1012 for venus. 3.9 × 1012 and 7.8
× 1012 for αSyn; 7.7 × 1012 for vector.
Authors who performed viral injections were blind to vector group
information. Sample sizes were determined by power calculation to
provide 80% power to detect 20–30% biologically meaningful changes
in primary outcome measure (nigral dopaminergic neuron counts)
based on our published estimates of mean ± SEM among WT (Chen
et al., 2013) and one-way ANOVA with Tukey post-hoc test at p b 0.05.
2.4. Behavioral Testing
Locomotor activity was assessed using the open ﬁeld test as de-
scribed (Chen et al., 2017; Graham and Sidhu, 2010). Mice were placed
in the activity chamber (11 × 11 in. with clear 8-in. high walls) and
monitored by an infrared video tracking system for 10 min (Ethovision
XT 9.0, Noldus Information Technology, The Netherlands). Tests were
conducted in the ﬁrst hour of the dark cycle on two consecutive days.
Averages of the distance traveled, active time duration and velocity
from the two sessions were calculated.
Amphetamine-induced (5 mg/kg i.p.) rotational behavior was
assessed in an automated rotometry system (San Diego Instruments)
for 60 min as described previously (Chen et al., 2017).
2.5. Immunostaining and Quantitative Analysis
Animals were sacriﬁced, and their brains were dissected, post-ﬁxed
in 4% paraformaldehyde overnight, cryoprotected in 30% sucrose and
sectioned coronally as previously described (Chen et al., 2017). Sections
were processed accordingly and incubatedwith primary antibodies. Pri-
mary antibodies were: mouse monoclonal antibody against αSyn
(Thermo Fisher Scientiﬁc Cat# AHB0261, RRID:AB_2536241, at 1:500),
mouse monoclonal antibody against pSer129-αSyn (BioLegend Cat#
825701, RRID:AB_2564891, at 1:500), mouse monoclonal antibody
against astrocytes marker glial ﬁbrillary acidic protein (GFAP, Sigma-
Aldrich Cat# G3893, RRID:AB_477010, at 1:2500), rabbit monoclonal
antibody against microglia marker ionized calcium-binding adapter
molecule 1 (iba-1, Abcam Cat# ab178846, RRID:AB_2636859, at
1:2000), and rabbit polyclonal antibody against dopaminergic neuron
marker tyrosine hydroxylase (TH, Enzo Life Sciences Cat# BML-SA497-
0100, RRID:AB_2052772, at 1:1000). For peroxidase staining, sections
were incubatedwith appropriate secondary antibodies and the staining
was developed by incubating with 3,3′-Diaminobenzidine (DAB). For
ﬂuorescent TH staining, sections were incubated with goat anti-rabbit
lgG-Alexaﬂuor 546 Alexa (Thermo Fisher Scientiﬁc Cat# A-11010,
RRID:AB_2534077, at 1:1000). Sections were covered by ProLong™
Gold Antifade Mountant with 4′,6-diamidino-2-phenylindole (DAPI)
nuclear staining after serial washes.
For analysis of GFAP staining and YFP ﬂuorescence intensity, images
were captured under an Olympus BX50 microscope (Olympus Optical
Co., Tokyo, Japan) with a DP 70 digital camera system using the same
camera gain, exposure time and pixel setting for all sections. Integrated
optical density (IOD) of GFAP staining in images taken under ×40 objec-
tivewas analyzed by Image J. Twomidbrain sections containing the cen-
tral and anterior SN permousewere analyzed. YFP ﬂuorescence average
intensity above background in the ipsilateral SNwas analyzed by ImageJ
using images taken under ×10 objective.
Morphology of iba1-positive cells in the SN pars compacta (SNpc)
was analyzed and classiﬁed according to the published method by
Sanchez-Guajardo et al. (2010). Based on their morphological charac-
teristics, iba1-positive cells were classiﬁed as resting (type A, visible
thin cytoplasm with long and thin processes), activated (type B, dense
and enlarged cell body with thick, short processes), and phagocytic
(type C, pseudo-amoeboid shape, big, dark cell body merging with pro-
cesses)microglia. Cellswere classiﬁed and counted cell by cell using ste-
reological method at 40× magniﬁcation (Olympus BX51 microscope
and Olympus CAST stereology software) as previously described
(Dimant et al., 2013;West et al., 1991). Twomidbrain sections contain-
ing the central and anterior SN per mouse were analyzed. Percentage of
each cell type was calculated.
2.6. Stereological Analysis of Nigral Dopaminergic Neurons
For dopaminergic neuron counts, a complete set of serial SN sections
at 30 μm from each animal was stained for TH and counterstained for
Nissl substance (Chen et al., 2013, 2017). Sections were coded and the
number of TH-positive cells was counted by unbiased stereology
based on the optical fractionator principle using Olympus BX51 micro-
scope and Olympus CAST stereology software, as previously described
(Dimant et al., 2013; West et al., 1991).
2.7. Proteinase K Digestion
Proteinase K (PK) digestion was performed as previously reported
(Dimant et al., 2013). Brieﬂy, brain sectionsweremounted on the slides,
and dry sectionswere rehydrated in TBS buffer containing 0.05% tween-
20 (PH7.4). Sections were then treated with 50 μg/ml PK at 55 °C for
120 min.
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2.8. Sequential Tissue Extraction and Immunoblot Analysis of Human αSyn
Animals were sacriﬁced and ventral midbrain and striatum were
dissected. Protein sequential extractionwas conducted as previously re-
ported with some modiﬁcations (Harms et al., 2013). Brieﬂy, tissues
were homogenized in RIPA buffer containing 1% Triton X-100 and pro-
tease inhibitor then centrifuged. Supernatants were designated as “Tri-
ton X-100 soluble” fractions. Pellets were resuspended in TBS buffer
containing 10% SDS and protease inhibitor and centrifuged. The super-
natants were designated as “SDS soluble” fractions. Fractions were
then subjected to NuPAGE SDS-PAGE gel (Thermo Fisher
Cat#NP0322), and Western blot analysis was performed using anti-
human αSyn antibody (Thermo Fisher Scientiﬁc Cat# AHB0261,
RRID:AB_2536241, at 1:1000). Pan-actin (Thermo Fisher Scientiﬁc
Cat#MS-1295, RRID:AB_63314)wasprobed as loading control. After in-
cubation with secondary antibodies, signal was detected using en-
hanced chemiluminescence.
2.9. Measurement of Dopamine Content
Animals were sacriﬁced and striatum were dissected. Dopamine
(DA) content was determined by standard high-performance liquid
chromatography (HPLC) with electrochemical detection, as previously
described (Chen et al., 2013; Xiao et al., 2006).
2.10. Statistical Analysis
Tissue process and outcome assessments were conduct in blind
manner wherever possible. All values are expressed as mean ± SEM.
The difference between groups was analyzed by Student's t-test or
ANOVA followed by Tukey post hoc test when an overall signiﬁcance
was demonstrated. p b 0.05 is considered statistically signiﬁcant.
3. Results
3.1. AAV8-mediated Human WT αSyn Overexpression in the SN, and αSyn
Oligomerization Detected by BiFC in Mice
Increasing evidence supports that pathologic αSyn oligomers are
strongly correlated to neurodegeneration in PD (Bengoa-Vergniory
et al., 2017; Kalia et al., 2013). BiFC is a powerful and widely used tool
to study protein-protein interactions in vitro and in vivo
(Paulmurugan et al., 2004; Tetzlaff et al., 2008). As illustrated in
Fig. 1a, Venus is fragmented into N and C termini, then fused with
human WT αSyn to form non-ﬂuorescent fusion proteins V1S and
SV2, respectively (Dimant et al., 2013). When αSyn forms oligomers,
the fused complementary N- and C-terminal halves of venusYFP com-
bine, reconstituting a full, ﬂuorescent complex. Therefore, venusYFP
ﬂuorescence can serve as an indicator for αSyn oligomerization.
The V1S SV2mixture as well as venus control were injected into the
SN. At 4 weeks post-injection, venusYFP ﬂuorescence (green) was ob-
served in the SN both in venus-injected and in V1SSV2-injected mice
(Fig. 1b). Colocalizationwith TH immunoﬂuorescence revealed success-
ful transduction and reconstitution of venusYFP upon αSyn oligomeri-
zation in nigral dopaminergic neurons. No ﬂuorescence was observed
in the non-injected contralateral side. All sections were counterstained
with 4′, 6-diamidino-2-phenylindole (DAPI, blue) to visualize nuclei.
To further conﬁrmAAV humanαSyn transduction in the SN,we per-
formed immunoperoxidase staining using a human speciﬁc αSyn anti-
body at 4 weeks after V1SSV2 injection. Positively stained cells were
observed in the entire SN on the ipsilateral side (Fig. 1c). No speciﬁc
staining was detected on the contralateral side as expected (Fig. 1c).
Fluorescent staining also showed robust human αSyn transduction on
the injection side in V1SSV2-injected mice. Colabeling for TH revealed
transduction and oligomerization of αSyn in dopaminergic neurons in
the SN (Fig. 1d). To assess whether αSyn detected by conjugated
venusYFP is soluble oligomers, SN sections were treated by proteinase
K. VenusYFP ﬂuorescence was diminished after the treatment. This re-
sult suggests soluble nature of αSyn oligomerization at 4 weeks post-
AAV injection (Fig. 1e).
3.2. Nigral Overexpression of HumanWT αSyn Induces Synucleinopathy in
the SN and Striatum
To determinewhether targeting humanWTαSyn overexpression to
the SN leads to pathological characteristics, coronal sections containing
SN and striatum were examined by ﬂuorescence microscopy. Intense
venusYFP ﬂuorescence in the ipsilateral SN was observed under low
magniﬁcation in animals 8 weeks after injection with venus or
V1SSV2 (Fig. 2a). VenusYFP ﬂuorescence in the ipsilateral striatum
was also visible. Higher magniﬁcation revealed ﬂuorescence in both
cell bodies and projections. In the striatum ﬂuorescent ﬁbers but no
cell proﬁles were observed, conﬁrming speciﬁc, anterograde transduc-
tion of venus or V1SSV2 and αSyn oligomerization along the
nigrostriatal dopaminergic projections (Fig. 2a). No ﬂuorescence was
observed in the contralateral sides of SN and striatum.Despite their sim-
ilar ﬂuorescence intensity and localization, venus and V1SSV2 groups
showed different ﬂuorescence patterns.While smooth andmore evenly
distributed in cell bodies and ﬁbers in venus-injected mice, a beaded
and punctate venusYFP ﬂuorescence pattern was observed in the SN
and the striatum of V1SSV2-injected animals (Fig. 2a). The abnormal
venusYFP ﬂuorescent structures were colabeled with TH, indicating do-
paminergic αSyn pathology (Fig. 2a).
To assess again whether αSyn aggregates detected by venusYFP is
soluble at a later time point, SN sections from mice sacriﬁced at
12 weeks following V1SSV2 injection were treated with proteinase K.
Following proteinase K treatment, venusYFP ﬂuorescence was mostly
absent. This result suggests that majority of αSynmultimers assembled
by this time were still soluble oligomers. However, few remaining visi-
ble venusYFP puncta after proteinase K treatment may indicate forma-
tion of insoluble αSyn aggregates (Fig. 2b).
To further investigate synuclein pathologies in V1SSV2 mice, mid-
brain sections from V1SSV2 mice 12 weeks post-injection were immu-
nostained for pSer129-αSyn, a phosphorylated αSyn modiﬁcation at
serine 129 that correlates to αSyn aggregation and progressive neuro-
degeneration of PD (Anderson et al., 2006). pSer129-αSyn positive sig-
nal was observed in the ipsilateral SN reticulata (SNr) as well as SNpc
while no speciﬁc staining was found on the contralateral side
(Fig. 2d). High magniﬁcation showed round, condensed staining with
some beading similar to the reconstituted venusYFP ﬂuorescence pat-
tern. To probe the dominant species ofαSyn in ourmodel, we employed
Western blot using a human αSyn antibody. Sequential extractions of
the ventral midbrain and the striatum dissected from non-BiFC αSyn-
injected mice at 8 weeks post-transduction were analyzed. Multiple
high-molecular-weight bands of αSyn were detected in both the mid-
brain and the striatum ipsilateral to the injection side, indicating oligo-
merization and formation of toxic, high-molecular-weightαSyn species
from virus transduction (Fig. 2e). Visible bands on the contralateral side,
which has been observed in a previous study using same αSyn 211 an-
tibody (Harms et al., 2013) might be explained by cross-reaction of the
antibody with endogenous mouseαSyn that was not detectable by im-
munohistochemistry (Fig. 1c) but became detectable by Western blot
using sequential tissue extraction.
3.3. HumanWT αSyn Overexpression Induces Astrogliosis and Microgliosis
Chronic neuroinﬂammation is associated with dopaminergic neuro-
degeneration in PD (Hirsch and Hunot, 2009; More et al., 2013; Perry
and Holmes, 2014). Abnormal αSyn accumulation activates immune
cells, including brain resident astrocytes and microglia (Dimant et al.,
2013; Harms et al., 2013). To assess whether targeted BiFC αSyn over-
expression in the SN induces concomitant inﬂammatory responses,
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midbrain coronal sections from mice at 12 weeks post-injection were
analyzed (Fig. 3). Animals injected with V1SSV2 or venus were immu-
nostained for the astrocyte marker GFAP and microglia marker iba-1.
While venus injection did not change GFAP, there was signiﬁcantly
more GFAP immunoreactivity on the ipsilateral side compared to the
contralateral side in V1SSV2 group as conﬁrmed by IOD assessment
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(Fig. 3a and b). Astrocytes on the ipsilateral side in V1SSV2-injected
mice displayed enlarged bodies and ramiﬁcations, indicating activation
of these cells (Fig. 3a) (Braak et al., 2007).
Morphology-based classiﬁcation (Sanchez-Guajardo et al., 2010)
was employed to analyze microglia activation after virus transduction.
Microglia undergo signiﬁcant morphological changes from resting,
thin cell bodies with numerous branched extensions to activate, en-
larged cell bodies with fewer short and thick branches to pseudo-
amoeboid shaped phagocytic state. We identiﬁed and counted the
three subtypes of iba-1 stained cells. Microglia in venus-injected mice
were mostly resting cells. V1SSV2 transduction resulted in a signiﬁcant
increase in activated microglia and their further transformation to
phagocytic microglia. No phagocytic microglia were observed in
venus-injected mice (Fig. 3c and d). These data support that human
WT αSyn overexpression triggered inﬂammatory responses in the SN.
3.4. Human WT αSyn Overexpression Leads to Abnormal Motor Behavior
To accessmotor activities in ourmouse AAVαSynmodels, open ﬁeld
and rotational behavior tests were performed. Open ﬁeld was tested
14weeks after non-BiFCαSyn and vector virus injection and before sac-
riﬁce. Interestingly, αSyn mice tended to be more active. They showed
increased distance covered,movement duration time and velocity com-
pared to vector controls as shown in Fig. 4a, b, c and in representative
movement tracks at 7 min of a total 10 min session in Fig. 4d. Since
ourmodels are unilateral, we assessed amphetamine-induced rotation-
al behavior in animals injected with V1SSV2 and venus control virus at
11 weeks post-injection (Chen et al., 2013, 2017). Amphetamine in-
duces release and inhibits reuptake of DA in the striatum leading to pre-
dominantly ipsilateral turning behavior in animals with unilateral
nigrastriatal lesions (Brooks and Dunnett, 2009; Iancu et al., 2005).
While venus-injected mice did not tend to turn towards either side,
there was an unexpected trend towards more contralateral turn and
less ipsilateral turns in V1SSV2 mice, and V1SSV2 animals exhibited a
signiﬁcant increase in contralateral turns vs ipsilateral turns following
amphetamine stimulation (Fig. 4e).
3.5. Reduced Striatal DA Content Induced by HumanWT αSyn Overexpres-
sion in the SN
To characterize dopaminergic phenotypes in our mouse AAV αSyn
models, we assessed striatal DA content using HPLC. Since YFP can po-
tentially cause toxicity, we injected mice with higher (4.4
× 1012 gc/ml, venus-H) and lower (0.6 × 1012 gc/ml) doses of venusYFP
and compared venusYFP at these two titers with non-BiFC empty vector
at 7.7 × 1012 gc/ml. At 12 weeks post-injection, there was 3%, 8%, and
25% decrease in striatal DA content relative to the contralateral side in
vector, venus and venus-H group, respectively (Fig. 5a). The decrease
in venus-H group is statistically signiﬁcant compared with the contra-
lateral side, indicating toxicity of venusYFP at 4.4 × 1012 gc/ml, not
AAV8 vector itself, even at a higher titer.
To exclude this venusYFP toxicity, we measured venusYFP ﬂuores-
cence intensity in V1SSV2 (5.08 × 1012 gc/ml) and venus control
4 weeks post-injection, when transduction was robust as shown in
Fig. 1. While venusYFP ﬂuorescence intensity in V1SSV2 and venus
group showed no difference, venus-H group exhibited 2.4-fold higher
ﬂuorescence intensity compared to V1SSV2 (Fig. 5b). Based on these re-
sults, we selected venus group with matching ﬂuorescence intensity as
control for V1SSV2.
To assess whether there was a time effect of αSyn transduction on
striatal DA, we analyzed DA levels at 4 and 12 weeks after venus and
V1SSV2 injection (Fig. 5c and d). A 10%, non-signiﬁcant decrease at
4 weeks and a signiﬁcant 38% reduction at 12 weeks in striatal DA on
the injection sidewere revealed in V1SSV2 group. No signiﬁcant striatal
DA reduction was detected at either time point in venus group. These
results suggest progressive nigrostriatal lesion induced by αSyn over a
12-week timeframe.
We also evaluated striatal DA levels in mice injected non-BiFC αSyn
at 3.9 × 1012 gc/ml and a higher titer at 7.8 × 1012 gc/ml (αSyn-H) and
vector at 7.7 × 1012 gc/ml. αSyn at these two titers led to 24% and 50%
reductions in striatal DA, respectively, at 12weeks post-injection, signif-
icant changes compared to vector-injected control animals. BiFC
V1SSV2 (at 5.04 × 1012 gc/ml) on the other hand led to a 33% decrease
in striatal DA, also a signiﬁcant difference from control venus (at 0.6
× 1012 gc/ml, with matching venus ﬂuorescence) group (Fig. 5e). In ad-
dition, diminished density of striatal TH staining in V1SSV2-injected
mice on the injection side was indicated (Fig. 5f). These results suggest
dose- and time- dependent DA reduction induced by AAV αSyn.
3.6. Loss of Nigral Dopaminergic Neurons Induced by Human WT αSyn
Overexpression
To assess whether humanWTαSyn overexpression led to loss of do-
paminergic neurons, serial midbrain sections were immunostained for
TH and the number of TH-positive cells were counted by an unbiased
stereological method. V1SSV2-injected mice had 3460 ± 201 TH-
positive neurons on the side ipsilateral to the injection, statistically dif-
ferent from 4897 ± 238 on the contralateral non-injection side at
12 weeks following virus injection, and statistically different from the
lesion side of venus-injected mice (5090 ± 452), which showed no
change in TH-positive cells on the injection side comparedwith contra-
lateral non-injection side (Fig. 6 a and b). Nissl counterstaining and ste-
reological counting of TH-negative neurons in the SNpc revealed no
difference between contralateral and ipsilateral sides in V1SSV2 group.
Nor was there difference in number of TH-negative neurons on the ipsi-
lateral side between venus and V1SSV2 groups (Fig. 6b). Total counts of
TH-positive and TH-negative cells, which reﬂect total number of neu-
rons in the SNpc were signiﬁcantly lower on the ipsilateral side in
V1SSV2-injected mice as compared to venus-injected mice (4640 ±
225 vs 6223 ± 501, p b 0.05). The total counts on the ipsilateral side
were also lower in the SNpc in V1SSV2-injected mice when comparing
to the contralateral side of the same group (4640± 225 vs 6056± 258,
p b 0.05). These ﬁndings supportαSyn-mediated toxicity in the SNpc at
12 weeks was dopaminergic neuron-speciﬁc.
To characterize the time course of dopaminergic cell loss, we
assessed an earlier time point, 4 weeks post-transduction and a later
time point, 22 weeks post-injection along with the 12 weeks time
point. Consistent with striatal DA changes, there were 8%, 29% and
33% losses of dopaminergic neuron counts at 4, 12 and 22 weeks, re-
spectively (Fig. 6c). These results suggest progressive dopaminergic
neurodegeneration induced by αSyn injection between 4 weeks and
12 weeks and a relative plateau state after to up to 22 weeks.
4. Discussion
Tremendous effort has been made to generate αSyn-based genetic
animalmodels of PD since the identiﬁcation ofαSynmutations in famil-
ial PD. Transgenic and AAV-mediated animal models overexpressing
Fig. 1. AAV8-mediated human WT αSyn expression in the SN and αSyn oligomerization detected by BiFC in mice at 4 weeks post-AAV injection. (a) Schematic structures of venus and
αSyn-BiFCs (V1S and SV2). Upper right illustrates reconstitution of venusYFP ﬂuorescence by αsyn-αsyn interactions. (b) TH immunoﬂuorescence and venusYFP ﬂuorescence in the
SN. Tissue sections were counterstained with DAPI (blue). Scale bar: 30 μm. (c) Immunohistochemistry of human αSyn in the SN after V1SSV2 injection. Tissue sections were
counterstained with hematoxylin (blue). Scale bars: 100 μm (left), 10 μm (right). (d) immunoﬂuorescent double staining for TH and human αSyn and their colocalization with
venusYFP in the SN after V1SSV2 injection. (e) VenusYFP before and after proteinase K treatment (PK− and PK+) in the SN following V1SSV2 injection. Scale bar: 30 μm.
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αSyn have advanced preclinical therapeutic development as well as our
understanding of PD pathophysiology. Based on the previous validation
of AAV-mediated intranigral overexpression of humanWT αSyn in rats
and mice and the recent further development of an AAV8 human WT
αSyn BiFC rat model, we report here successful application of this BiFC
system in mice despite greater technical demands. The mouse model
displays robust αSyn transduction and oligomerization, neuroinﬂam-
mation,motor deﬁcits, and reduced striatal DA and loss of dopaminergic
neurons that are comparable to non-BiFC vectors.
Consistent with the rat model, overexpression and oligomerization
of αSyn are detected by reconstituted venusYFP ﬂuorescence, and fur-
ther conﬁrmed by our immunohistochemistry and immunoblotting
using antibody against human αSyn. Intracellularly, venusYFP ﬂuores-
cence is distributed in both cell bodies and neurites. In contrast to the
demonstration of healthy cells transduced with venus, venusYFP ﬂuo-
rescence generated by αSyn oligomerization shows the appearance of
distorted, punctate cellular morphology with beaded, dystrophic
neurites, supporting pathogenic effects of αSyn oligomerization. Detec-
tion of venusYFP ﬂuorescence and similar appearance of abnormal,
beaded axon terminals in the striatum indicates effective anterograde
transport of αSyn formed through the BiFC system along the
nigrostriatal dopaminergic projections. Soluble oligomers are likely
the pathological species in our model, which is overall consistent with
our previous ﬁnding in rats (Dimant et al., 2013) though insoluble
αSyn aggregates cannot be excluded given sparse but visible venusYFP
ﬂuorescence after proteinase K treatment at 12 weeks. Theoretically
αSyn ﬁbrils, if any, may also emit ﬂuorescence. Using similar protein
fragment complementation assay, we have detected in vitro the pres-
ence of extracellular αSyn oligomers and their detrimental effects on
neighboring cells (Danzer and Kranich, 2012; Danzer et al., 2011). Our
BiFC mouse model may facilitate detection of possible αSyn transmis-
sion in vivo.
Reduced striatal DA content, the core neurochemical feature of
human PD, is demonstrated in our mouse models expressing human
WTαSynmediated by both BiFC and non-BiFC.Withmatching intensity
of venusYFP ﬂuorescence to venus control, BiFC αSyn induced a pro-
gressive reduction in DA levels in the striatum between 4 and
12weeks after viral transduction. Reduced striatal DAhas been reported
in an AAV1/2 A53T αSyn mouse model with a similar virus titer at
10 weeks (Ip et al., 2017). This reduction appears to be dose-
dependent as well, as demonstrated by non-BiFC αSyn overexpression,
which induces corresponding 50% and 24% reduction at a higher titer
and at a lower, half titer. The higher titer matches non-toxic empty vec-
tor. These ﬁndings suggest that the effect on striatal DA is likely related
to αSyn-speciﬁc toxicity. Of note, at the same titer, venusYFP generates
over 2-fold more intense venusYFP ﬂuorescence than V1SSV2. This is
expected since reconstruction of one venusYFP molecule takes at least
two αSyn molecules. More venusYFP may explain reduced DA by high
Fig. 2.HumanαSyn transduction induces synucleinopathies. (a) VenusYFP ﬂuorescence in the striatum, venusYFP ﬂuorescence and its colacalizationwith TH in the SN 8weeks following
venus or V1SSV2 injection. Arrows indicate beaded, dystrophic neurites. Scale bars: 100 μm(left), 10 μm(right). (b) VenusYFP before and after proteinase K treatment in the SN 12weeks
following V1SSV2 injection. Scale bars: 20 μm. (c) Immunohistochemistry for pSer129 αSyn in the SN 12 weeks following V1SSV2 injection. Scale bars: 50 μm (left), 10 μm (right).
(d) Accumulation of high-molecular-weight-αSyn species in the ventral midbrain and the striatum 8 weeks following V1SSV2 injection by Western blot analysis using anti-human
αSyn antibody. Tissue sequential extractions were prepared using Triton X-100 and SDS.
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venus titer, which is not shown in mice injected with non-BiFC empty
vector even at a higher titer, supporting toxicity of excessive venusYFP,
not AAV8 itself (Klein et al., 2006).
Alteredmotor behavior is observed in our AAVαSynmice. Increased
travel distance, movement duration and velocity in open ﬁeld are dem-
onstrated. Although behavioral phenotypes in αSyn models are not
Fig. 3. Human αSyn overexpression in the SN triggers astrogliosis and microgliosis at 12 weeks post-AAV injection. (a) Midbrain coronal sections immunostained for GFAP from mice
injected with venus or V1SSV2 injection. (b) Quantiﬁcation of GFAP staining IOD. Venus, n = 6; V1SSV2, n = 7. (c) Midbrain coronal sections immunostained for iba1 from mice
injected with venus or V1SSV2 injection. (d) Morphological classiﬁcation of iba1-positive cells in the SNpc. Type A, resting, Type B, activated, Type C, phagocytic. n= 4 per group. Scale
bars: 50 μm (left), 10 μm (right). Data are expressed as mean ± SEM ∗p b 0.05, ∗∗∗p b 0.001 ANOVA followed by Tukey's post hoc test. # indicates phagocytic microglia identiﬁed in
V1SSV2 group only.
Fig. 4. Human αSyn expression in the SN is associated with abnormal locomotor activity and rotation behavior in mice. Total distance traveled (a), moving duration time (b), velocity
(c) and representative movement tracks (d) by open ﬁeld test 14 weeks post virus injection. n = 5 per group, average of data from two sessions. Amphetamine induced rotations
11 weeks post-injection (e). Venus, n = 6; V1SSV2, n = 7. Data are expressed as the means ± SEM ∗p b 0.05 student t-test (a–c), ANOVA followed by Turkey's post hoc test (e).
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well-established and often variable, motor deﬁcits such as decreased lo-
comotion are observed in αSyn transgenic mice (Graham and Sidhu,
2010; Koprich et al., 2017; Unger et al., 2006). Unexpected hyperactivity
has been demonstrated in both A53T αSyn transgenic mice (Rothman
et al., 2013), which can be attributed to anxiety (Farrell et al., 2014),
and A30P αSyn transgenic mice (Freichel et al., 2007). However,
hypo- or hyper- activities in these models do not always correlate
with nigrostrital dopaminergic dysfunction (Chesselet and Richter,
2011; Koprich et al., 2017). Neither A53T nor A30P αSyn transgenic
mice demonstrate signiﬁcant dopaminergic cell death. It is possible
that the motor abnormalities reﬂect neuronal dysfunction rather than
dopaminergic neurodegeneration (Peelaerts and Bousset, 2015). A30P
αSyn transgenic mice, for example, display increased extracellular DA
at 6 months of age. The exact mechanisms underlying increased loco-
motor activity in our model are unclear. Similarly, it remains to be elu-
cidated why BiFC αSyn mice tend to rotate contralateral to the lesion
side. Typical parkinsonian behavioral changes such as motor
hypoactivity and ipsilateral turns in unilateral models of PD are usually
associated with extensive nigrostriatal lesion in the nigrostriatal path-
way, mostly toxin induced (Schober, 2004). An AAV2/7 αSyn mouse
model with ~70% nigral dopaminergic neuron death shows
hypoactivities in open ﬁeld (Oliveras-Salvá et al., 2013) and an AAV6
αSyn rat model with 80% loss of dopaminergic neurons display ipsilat-
eral turns (Decressac et al., 2012). Compensatory modulation of DA re-
ceptors in response to relatively moderate DA reduction might also be
involved in the unexpected behavioral changes in our model (Bezard
and Gross, 1998; Stricker et al., 2011).
Ourmousemodels show time-dependent loss of dopaminergic neu-
rons in the SN, the cardinal pathological feature of PD. Plateaued reduc-
tion by one third between 3 and 5 months following viral αSyn
transduction is in agreement with previously reported mild (~25%) do-
paminergic neuron loss in AAV αSyn mouse models (Cao et al., 2010;
Harms et al., 2013; St Martin et al., 2007). Likewise, the lesion we dem-
onstrated is slightly less than the average 45% dopaminergic neuron loss
observed in rats (Dimant et al., 2013), asmay be expected due to differ-
ence in species, virus titer (5 vs 8.5 × 1012 vg/ml) and time points (12 vs
Fig. 5. Human αSyn expression in the SN leads to reduced striatal DA measured by HPLC. (a) Striatal DA levels. Vector, n = 4, Venus, n = 6, Venus-H, n = 7, 12 weeks post-injection.
(b) YFP ﬂuorescence intensity in the SN 4 weeks post-injection. V1SSV2, n = 7, Venus-H, Venus, n= 6. (c–d) Striatal DA levels 4 and 12 weeks post-injection. Venus/4 weeks, n = 7;
V1SSV2/4 weeks, n= 8; Venus/12 weeks, n = 6, V1SSV2/12 weeks, n= 12. (e) Striatal DA levels from mice 12 weeks after injection with BiFC vectors (Venus and V1SSV2) and non-
BiFC vectors (Vector, αSyn). Venus n = 6, V1SSV2, n = 12; vector, n = 4, αSyn-H, n = 12, αSyn, n = 7. (f) Representative striatal TH immunohistochemistry from a V1SSV2-injected
mouse at 12 weeks. Data are expressed as the means ± SEM. #p b 0.05 student t-test, ipsilateral side vs contralateral side. ∗p b 0.05, ∗∗p b 0.01, ∗∗∗p b 0.001 ANOVA followed by Tukey's
post hoc test.
Fig. 6. Human αSyn expression in the SN leads to loss of dopaminergic neurons. (a) Representative SN sections immunostained for TH at 12 weeks post-injection. Scale bar: 100 μm.
(b) Stereological quantiﬁcation of nigral TH-positive and TH-negative cells 12 weeks post-injection. Venus, n = 4, V1SSV2, n = 6. (c) Stereological quantiﬁcation of nigral TH-positive
neurons from mice 4, 12, 22 weeks post- V1SSV2 injection. n = 6, n = 7, n = 4 per 4, 12, 22w groups. Data are expressed as the means ± SEM ∗p b 0.05, ∗∗∗p b 0.001, ANOVA
followed by Tukey's post hoc test.
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8weeks). Demonstration of dopaminergic neuron loss at an earlier time
point in BiFCαSyn mice at 12 weeks than typical 24 weeks in non-BiFC
αSyn (Cao et al., 2010; Harms et al., 2013; StMartin et al., 2007)may be
contributed to different virus serotype (AAV8 vs AAV2 or mixture of
AAV2&8) (Albert et al., 2017; Klein et al., 2006; Watakabe et al.,
2015). It has been demonstrated that aSyn multimerization in protein
complementation assays is not driven by the tags (Outeiro et al., 2008;
Wang et al., 2014), and we do not ﬁnd evidence for enhanced effects
of BiFC αSyn vs non-BiFC αSyn. The extent of nigral neuronal cell
body loss is overall consistent with DA reduction (38%) in the striatum,
suggestingαSyn-induced dopaminergic neurodegeneration in the SNas
the main cause for associated DA depletion in the striatum.
The accompanying gliosis andmicrogliosis that we show in our BiFC
αSyn mice are consistent with well-characterized neuroinﬂammation
in AAV αSyn rat and mouse models, suggesting prolonged inﬂammato-
ry responses and potential role of activated astrocytes and microglia in
dopaminergic neurodegeneration triggered by αSyn. However, mecha-
nisms contributing to eventual neurodegenerative consequences of
human αSyn overexpression and oligomerization are not fully under-
stood. Our systematically validated model facilitating ﬂuorescence de-
tection of αSyn oligomerization along with non-BiFC αSyn mouse
model may provide a useful tool to investigate such underlying mecha-
nisms and to explore therapeutic approaches for PD. AAV1/2 have been
described to mediate αSyn overexpression in oligodendrocytes (Bassil
et al., 2017). However, since the ability of our vectors to transduce
glial cells has not been characterized, using this technique to model
other synucleinopathies such asmultiple system atrophywould require
further validation.
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